Effect of anlotinib combined with camrelizumab on clinical efficacy and short-term prognosis in male patients with advanced gastric cancer

Ítems similars

• Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study
  per: Shujing Shen, et al.
  Publicat: (2024-07-01)
• Efficacy and toxicity of anlotinib plus camrelizumab versus anlotinib plus S-1 as second-line therapy for advanced esophageal squamous cell carcinoma: A real-world retrospective study
  per: Wei Zhang, et al.
  Publicat: (2024-10-01)
• SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report
  per: JiKe Hu, et al.
  Publicat: (2024-07-01)
• An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma
  per: Yunqian Chu, et al.
  Publicat: (2024-08-01)
• The efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcoma
  per: Ying Ni, et al.
  Publicat: (2024-10-01)